Yiming Cheng

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Tyrosine Kinase

Multiple Myeloma

Top Venues

Clinical pharmacology : advances and applications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

British journal of clinical pharmacology

Journal of clinical pharmacy and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Yiming Cheng, Shuyu Chu, Jie Pu, Min Chen, Kevin Hong, Paulo Maciag, Ivan Chan, Li Zhu, Akintunde Bello, Yan Li
Exposure-Response-Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Yiming Cheng, Ying Ye, Allison Gaudy, Atalanta Ghosh, Yongjun Xue, Alice Wang, Simon Zhou, Yan Li
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects. Clinical pharmacology : advances and applications 15 (2023)
Yiming Cheng, Ying Ye, Allison Gaudy, Atalanta Ghosh, Yongjun Xue, Alice Wang, Simon Zhou, Yan Li
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects. Clinical pharmacology : advances and applications 15 (2023)
Yiming Cheng, Liangang Liu, Yongjun Xue, Simon Zhou, Yan Li
An open-label, phase 1, randomized, three treatments, three-period, crossover, relative bioavailability study of CC-292, a potent and orally available inhibitor of bruton tyrosine kinase. Journal of clinical pharmacy and therapeutics 47 (8) (2022)
Yiming Cheng, Yongjun Xue, Lu Chen, Mark Masin, Paulo Maciag, Teresa Peluso, Simon Zhou, Yan Li
Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma. British journal of clinical pharmacology (2022)
Yiming Cheng, Kevin Hong, Nianhang Chen, Xin Yu, Teresa Peluso, Simon Zhou, Yan Li
Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients. EJHaem 3 (3) (2022)